Related Experiment Videos
Oncogene profile of papillary thyroid carcinoma
Surgery
|January 16, 1999
Summary
Papillary thyroid cancer oncogene expression reveals ret/PTC rearrangements in 40% of cases, potentially driving metastasis. Ras mutations are rare, and erbB-2/neu amplification is absent, suggesting limited cumulative oncogene roles.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Papillary thyroid carcinoma (PTC) is a common thyroid malignancy.
- Understanding oncogene expression and interactions is crucial for determining prognostic significance.
Purpose of the Study:
- To investigate the expression and potential interactions of key oncogenes (ras, ret/PTC, erbB-2/neu) in papillary thyroid cancer.
- To assess the prognostic significance of these oncogenes in PTC.
Main Methods:
- Analysis of ras, ret/PTC, and erbB-2/neu oncogenes in 20 papillary thyroid carcinomas.
- Utilized polymerase chain reaction (PCR), reverse transcription (RT-PCR), sequencing, and immunohistochemistry for expression and mutation analysis.
Main Results:
- ret/PTC rearrangements were detected in 40% of tumors, associated with metastatic behavior.
- Ras mutations were found in 10% of tumors.
- No erbB-2/neu amplification or mutations were observed, though elevated mRNA levels were present in 20%.
Conclusions:
- ret/PTC rearrangements are frequent in PTC and may contribute to metastasis.
- Ras mutations are infrequent, and erbB-2/neu alterations are not common drivers.
- The limited correlation among these oncogenes suggests they are not typically cumulative factors in PTC pathogenesis.